HAEのチャート
HAEの企業情報
| symbol | HAE |
|---|---|
| 会社名 | Haemonetics Corp. （HAE ヘモネティクス） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ヘモネティクス(Haemonetics Corporation)はヘルスケア会社である。同社は顧客向けに血液加工・取扱・分析に従事する。同社のセグメントには日本、EMEA、北米プラズマと他を含む。同社は、血漿分画装置が医薬品を製造することを可能にする血漿収集システムおよびソフトウェアを提供する。同社は血漿採取顧客が「PCS」というブランドの血漿採取器具および使い捨て器具、血漿採取容器および生理食塩水を含む血漿採取・保存に必要な製品の供給源を得ることを可能にする。同社は自動化血液成分および手動全血採取システムを採血センターに提供し、血液製剤を収集する。同社は血液管理ソリューションを提供する。同社には血液駆動計画と血液採取のためのソリューションを含む統合ソフトウェアソリューションがある。 ヘモネティクスは、米国のヘルスケア企業。血漿から血液採取装置、医療機関まで血液サプライチェ―ンの各段階に合わせた血液管理ソリュ―ションの他、集積デバイス、情報管理、およびコンサルティングサ―ビスを提供する。同社の製品は、血漿、血液センタ―、病院、ソフトウェアソリュ―ションに分かれる。 Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. |
| 本社所在地 | 781 848-7100 |
| 代表者氏名 | Christopher Simon |
| 代表者役職名 | President Chief Executive Officer Director |
| 電話番号 | +1 781-848-7100 |
| 設立年月日 | 1971年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 3136人 |
| url | www.haemonetics.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 209.40200 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 4462.11800 |
| 売上高 | 売上高（百万ドル） 951.83600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4651.06400 |
| 当期純利益 | 当期純利益（百万ドル） 45.76400 |
| 決算概要 | 決算概要 BRIEF: For the 39 weeks ended 29 December 2018 Haemonetics Corporation revenues increased 7% to $718.3M. Net income before extraordinary items decreased 45% to $34.2M. Revenues reflect North America Plasma segment increase of 19% to $295.4M All other segment increase of 4% to $250.6M Japan segment increase of 3% to $52.2M United States segment increase of 10% to $452.5M Asia segment increase of 4% to $89.1M Japan segment increase of 6% to $52.3M. |
HAEのテクニカル分析
HAEのニュース
Haemonetics Stock: Executing Well, Valuation Concerns (NYSE:HAE) 2023/02/16 02:00:14 Seeking Alpha
Haemonetics surpassed sell-side expectations with healthy revenue growth from Plasma and Hospital. Read why I think HAE stock merits a closer look.
Haemonetics Corporation (HAE) Q3 2023 Earnings Call Transcript 2023/02/07 19:17:06 Seeking Alpha
Haemonetics Corporation (NYSE:NYSE:HAE) Q3 2023 Earnings Conference Call February 7, 2023 8:00 AM ETCompany ParticipantsDavid Trenk - Manager, Investor RelationsChris Simon - Chief…
Haemonetics: Earnings Rate Of Change Justifies High Multiples (NYSE:HAE) 2023/02/01 15:00:25 Seeking Alpha
Haemonetics continues to catch a strong bid in FY23'' having clipped a 74% gain over the past 12 monts. See why we reiterate buy on HAE stock.
Haemonetics (HAE) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow (NYSE:HAE) 2023/01/11 18:46:58 Seeking Alpha
The following slide deck was published by Haemonetics Corporation in conjunction with this event.
Plasmapheresis Machines Market to Witness Huge Growth by Key Players: Fresenius Medical Care, Haemonetics Corporation, Fenwal, Terumo BCT, Nikkiso 2022/12/04 05:25:15 OpenPR
The Plasmapheresis Machines research report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company
Plasmapheresis Machines Market to Witness Huge Growth by Key Players: Fresenius Medical Care, Haemonetics Corporation, Fenwal, Terumo BCT, Nikkiso 2022/12/04 05:25:15 OpenPR
The Plasmapheresis Machines research report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company
Haemonetics Corporation (HAE) Q2 2023 Earnings Call Transcript 2022/11/07 16:17:04 Seeking Alpha
Haemonetics Corporation (NYSE:NYSE:HAE) Q2 2023 Earnings Conference Call November 7, 2022 8:00 a.m.
Haemonetics 2nd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website 2022/11/07 11:00:00 Benzinga
Financial release accessible online BOSTON , Nov. 7, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE ) announced that financial results for its second quarter fiscal 2023, which ended October 1, 2022 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2022 . The conference call and webcast can be accessed with the following … Full story available on Benzinga.com
Haemonetics Q2 2023 Earnings Preview (NYSE:HAE) 2022/11/04 16:44:06 Seeking Alpha
Haemonetics (HAE) is scheduled to announce Q2 earnings results on Sunday, November 6th, before market open.The consensus EPS Estimate is $0.67 (+11.7% Y/Y) and the consensus…
Buy - Victory Capital Management Inc. Raises Position in Haemonetics Co 2022/10/24 13:07:18 Business Mag
Victory Capital Management Inc. grew its position in Haemonetics Co. by 808.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 377,252…
Haemonetics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference 2022/08/23 22:06:00 PR Newswire
BOSTON, Aug. 23, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 8:45 a.m. ET. The public may access Mr. Simon''s…
Haemonetics Director Sold $590K In Company Stock 2022/08/17 14:05:36 Benzinga
Mark W Kroll , Director at Haemonetics (NYSE: HAE ), reported a large insider sell on August 16, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Kroll sold 8,016 shares of Haemonetics . The total transaction amounted to $590,859. Haemonetics shares are trading down 0.72% at $75.77 at the time of this writing on Wednesday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to make an … Full story available on Benzinga.com
Haemonetics Corporation (HAE) CEO Chris Simon on Q1 2023 Results - Earnings Call Transcript 2022/08/10 17:42:11 Seeking Alpha
Haemonetics Corporation (NYSE:NYSE:HAE) Q1 2023 Earnings Conference Call August 10, 2022 08:00 AM ET Company Participants Olga Guyette - Director, IR and Treasury Chris Simon - CEO James…
Haemonetics: Q1 Earnings Insights 2022/08/10 10:35:23 Benzinga
Haemonetics (NYSE: HAE ) reported its Q1 earnings results on Wednesday, August 10, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Haemonetics beat estimated earnings by 13.73%, reporting an EPS of $0.58 versus an … Full story available on Benzinga.com
Earnings Scheduled For August 10, 2022 2022/08/10 09:33:06 Benzinga
Companies Reporting Before The Bell • Wix.com (NASDAQ: WIX ) is estimated to report earnings for its second quarter. • Xeris Biopharma Holdings (NASDAQ: XERS ) is expected to report earnings for its second quarter. • BiomX (AMEX: PHGE ) is likely to report earnings for its second quarter. • CSP (NASDAQ: CSPI ) is likely to report earnings for its third quarter. • Herbalife Nutrition (NYSE: HLF ) is projected to report quarterly earnings at $0.32 per share on revenue of $329.94 million. • Evaxion Biotech (NASDAQ: EVAX ) is likely to report earnings for its second quarter. • iShares Gold Trust Shares of the iShares Gold Trust (NYSE: IAU ) is likely to report earnings for its second quarter. • Innovid (NYSE: CTV ) is estimated to report quarterly loss at $0.03 per share on revenue of $33.33 million. • Vita Coco (NASDAQ: COCO ) is projected to report quarterly earnings at $0.08 per share on revenue of $115.02 million. • NextNav (NASDAQ: NN ) is likely to report quarterly loss at $0.10 per share on revenue of $1.